

## CFO Kristian Borbos to leave Ascelia Pharma

**Ascelia Pharma AB (publ) (ticker: ACE) today announced that CFO Kristian Borbos will leave the company to take up a similar position at the Danish biotech company Gubra.**

Kristian Borbos joined Ascelia Pharma in 2017 and was instrumental in the company's successful listing process to the main list of Nasdaq Stockholm in 2019.

"Kristian Borbos has played an important role in developing Ascelia Pharma into a Nasdaq listed company as well as building the capabilities that are essential for a well-functioning publicly traded company. I want to thank him for all his contributions and wish him success in his new role, knowing that he leaves behind a well-financed Ascelia Pharma with significant growth opportunities ahead", said Magnus Corfitzen, CEO of Ascelia Pharma.

Ascelia Pharma will initiate the process to find a successor. Kristian Borbos will continue in the role as CFO for Ascelia Pharma during the resignation period.

### Contacts

---

Magnus Corfitzen, CEO  
Email: [moc@ascelia.com](mailto:moc@ascelia.com)  
Tel: 46 735 179 118

Mikael Widell, IR & Communications  
Email: [mw@ascelia.com](mailto:mw@ascelia.com)  
Tel: +46 703 11 99 60

## About Us

---

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit <http://www.ascelia.com>.

### **About Orviglance** (previously referred to as Mangoral)

Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

### **About Oncoral**

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

## Attachments

---

**CFO Kristian Borbos to leave Ascelia Pharma**